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Abstract
Naegleria fowleri is a free-living amoeba that can also act as an opportunistic pathogen
causing severe brain infection, primary amebic meningoencephalitis (PAM), in humans. The
high mortality rate of PAM (exceeding 97%) is attributed to (i) delayed diagnosis, (ii) lack of
safe and effective anti-N. fowleri drugs, and (iii) difficulty of delivering drugs to the brain. Our
work addresses identification of new molecular targets that may link anti-Naegleria drug dis-
covery to the existing pharmacopeia of brain-penetrant drugs. Using inhibitors with known
mechanism of action as molecular probes, we mapped the sterol biosynthesis pathway of
N. fowleri by GC-MS analysis of metabolites. Based on this analysis, we chemically vali-
dated two enzymes downstream to CYP51, sterol C24-methyltransferase (SMT, ERG6)
and sterol Δ8−Δ7 -isomerase (ERG2), as potential therapeutic drug targets in N. fowleri. The
sterol biosynthetic cascade in N. fowleri displayed a mixture of canonical features peculiar
to different domains of life: lower eukaryotes, plants and vertebrates. In addition to the
cycloartenol!ergosterol biosynthetic route, a route leading to de novo cholesterol biosyn-
thesis emerged. Isotopic labeling of the de novo-synthesized sterols by feeding N. gruberi
trophozoites on the U13C-glucose-containing growth medium identified an exogenous origin
of cholesterol, while 7-dehydrocholesterol (7DHC) had enriched 13C-content, suggesting a
dual origin of this metabolite both from de novo biosynthesis and metabolism of scavenged
cholesterol. Sterol homeostasis in Naegleria may be orchestrated over the course of its life-
cycle by a “switch” between ergosterol and cholesterol biosynthesis. By demonstrating the
growth inhibition and synergistic effects of the sterol biosynthesis inhibitors, we validated
new, potentially druggable, molecular targets in N. fowleri. The similarity of the Naegleria
sterol Δ8−Δ7 -isomerase to the human non-opioid σ1 receptor, implicated in human CNS
conditions such as addiction, amnesia, pain and depression, provides an incentive to
assess structurally diverse small-molecule brain-penetrant drugs targeting the human
receptor for anti-Naegleria activity.
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Author summary
Sterols are important constituents of cell membranes. In a unicellurar organism, such as
the human pathogen N. fowleri, the cell membrane delineates the physical boundaries of
the cell and mediates interactions of the organism with its environment. N. fowleri is a
free-living amoeba that may infect the human brain causing a fulminant infection called
primary amebic meningoencephalitis (PAM). PAM has resulted in death in>97% of
reported cases. Understanding the molecular and cellular biology of N. fowleri will facili-
tate the rational development of new therapeutic interventions. Using inhibitors targeting
different enzymatic steps in the sterol biosynthesis pathway, we mapped metabolic inter-
mediates and delineated the biosynthetic routes contributing to N. fowleri sterol homeo-
stasis. An array of sterol molecules suggests that two different sterol types, ergosterol-like
and cholesterol-like sterols, co-exist and may be dynamically regulated in N. fowleri. Dis-
ruption of sterol biosynthesis by drug candidates was detrimental to N. fowleri. Drugs tar-
geting three different enzymatic steps resulted in growth inhibition effect. This effect was
amplified when drugs targeting different enzymes were combined. The observed synergis-
tic effect of these drugs lowers the individual drug concentrations required for biological
activity including delivering anti-PAM drugs across the blood-brain-barrier.
Introduction
Naegleria fowleri and its non-pathogenic relatives, Naegleria gruberi and Naegleria lovaniensies,
belong to the genus Naegleria, class Heterolobosea, which is characterized by a capacity for
quick differentiation from an amoeboid to a flagellate form. These amoebae feed mostly on
bacteria, but can also act as opportunistic pathogens causing infections of the central nervous
system (CNS) of humans and other animals. N. fowleri is the only species of the genus known
to cause a severe primary amebic meningoencephalitis (PAM) in humans.[1] Naegleria occur
in three forms–a cyst, a trophozoite (amoeboid), and a biflagellate. The trophozoite is the only
feeding and reproductive stage of Naegleria spp., as well as the only one found in infected
brain tissue[2], while the flagellate form was detected in the cerebrospinal fluid (CSF)[3]. PAM
due to N. fowleri has a worldwide distribution although it occurs most frequently in tropical
areas and during hot summer months.[4]
N. fowleri infection is problematic due to the rapid onset and destructive nature of the dis-
ease as well as to the lack of established success in treatment.[5] Until recently, no more than a
dozen patients out of ~350 reported PAM cases worldwide have been treated successfully with
Amphotericin B (AmpB), either alone or in combination with other drugs.[6–9]. The investi-
gational anti-cancer and anti-leishmaniasis agent miltefosine[10] showed promise, but not all
patients who received miltefosine as part of their treatment regimens survived. In 2013, two
patients survived out of three treated with miltefosine, but one of the survivors had permanent
brain damage.[11] In 2016–2017, two more patients receiving miltefosine survived out of 9
diagnosed with PAM. The lack of a single, proven, evidence-based treatment of PAM with a
high probability of cure stimulates a need to further study Naegleria biology in order to under-
stand molecular mechanisms maintaining N. fowleri homeostasis throughout different devel-
opmental stages and dietary conditions.
Sterols are an important class of lipids essential in all eukaryotes. It is assumed that the last
eukaryotic common ancestor (LECA) already synthesized sterols.[12] Eukaryotes that lost the
ability to synthesize sterols, e.g., insects, worms and most marine invertebrates, have to obtain
Sterol homeostasis in N. fowleri
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them from food. Sterols are involved in both intra- and intercellular signaling and in the orga-
nization of membranes. They affect fluidity and permeability of membranes and are major
players in the formation of lipid rafts, regions of reduced fluidity formed by the close associa-
tion of sterols with sphingolipids. [13–15] In unicellular organisms, lipid rafts control endocy-
tosis, vesicle trafficking, motility, and cell signaling and have been shown to regulate adhesion
to host cells and control virulence (reviewed in [16]). Ergosterol, a fungal and kinetoplastid ste-
rol, was shown to promote formation of the lipid rafts.[17]
By DNA sequence, Naegleria are close to kinetoplastids, however, in contrast to the lanos-
terol precursor in kinetoplastids,[18] de novo biosynthesis of ergosterol in amoebae occurs
from cycloartenol, a precursor typical of photosynthetic organisms, ie., algae and plants.[19–
21] Disruption of sterol biosynthesis by small-molecule inhibitors targeting CYP51 is detri-
mental for N. fowleri trophozoites, suggesting that ergosterol biosynthesis is essential for amoe-
boid survival.[22] Among the enzymes constituting the sterol biosynthetic pathway in
eukaryotes, several targets have been studied for the development of therapeutic or agricultural
agents. For instance, the HMG-CoA reductase inhibitors, known as statins, are drugs used for
lowering serum cholesterol. Farnesyl diphosphate synthase (targeted by bisphosphonates),
squalene synthase (aryloxyethyl thiocyanate and quinuclidine derivatives), squalene epoxidase
(terbinafine), oxidosqualene cyclase (pyridinium-ion mimetics), sterol 14α-demethylase
(CYP51) (azoles), sterol C24-methyltransferase (SMT) (arylguanidines, azasterols), and sterol
Δ8−Δ7 isomerase (ERG2) (morpholines) have been validated as drug targets to treat fungal
infections in humans and plants.
In this work, we have assessed the sterol biosynthesis pathway in N. fowleri downstream of
CYP51 by GC-MS analysis of the metabolic intermediates accumulated in trophozoites in
response to the inhibitors with known mechanisms of action (MOA). Using inhibitors as the
molecular probes, we chemically validated SMT and ERG2 as essential enzymes in N. fowleri.
In vitro growth inhibition effect were observed for inhibitors of each mechanistic group
applied individually. When applied in combination, inhibitors with different MOA produced
synergistic effects. The biosynthetic cascade reconstituted in N. fowleri, based on the flux of the
metabolic intermediates, indicates that the steroidogenic pathway bifurcates into ergosterol
and cholesterol arms. The observed sterol profile suggests a possibility of dynamic modulation
of sterol homeostasis in N. fowleri in response to environmental factors or dietary conditions.
Results and discussion
Sterol biosynthesis enzymes in Naegleria
Biosynthetically, sterols are derived from isopentenyl diphosphate (IPP), the precursor of
squalene and its downstream cyclized products. The first step leading to sterols adds an oxygen
to squalene resulting in squalene epoxide, which is then cyclized in a second step either to
lanosterol or to cycloartenol. Enzymes constituting the core sterol biosynthesis pathway in
eukaryotes largely exhibit strong conservation in amino acid sequences; however, the pathway
architecture and substrate specificity vary.[23] Steroidogenesis in the non-pathogenic environ-
mental Naegleria species, N. gruberi and N. lovaniences, was assessed in the pre-genomic era.
[20] Following up on results from earlier studies[22], we have now interrogated the sterol bio-
synthesis pathway in N. fowleri. Naegleria steroidogenic enzymes were identified by sequence
homology to the yeast, human and plant orthologues. They are characterized by high intra-
genus sequence similarities and lower similarity to the human counterparts, the latter ranging
from 32 to 56% for homologous enzymes (S1 Table). The Δ24-reduction and Δ8−Δ7 -isomeri-
zation steps are performed by non-homologous enzyme pairs (<20% sequence identity),
ERG4 and ERG2 in fungi, DHCR24/DWF1 and EBP/HYD1 in vertebrates/land plants
Sterol homeostasis in N. fowleri
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respectively. The Naegleria enzymes are homologous to fungal orthologues, suggesting that
both can be exploited therapeutically.
The 3-keto-steroid reductase and C22-desaturase could not be identified in Naegleria by
homology with yeast, human or plant counterparts. The Naegleria 3-keto-steroid reductase
that catalyzes the last of the three steps required to remove two C-4 methyl groups may be
homologous to yet unknown C-3 ketoreductase in land plants.[12] A protein with similarity to
CYP710A, equivalent to 22-desaturase in higher plants, is present in N. gruberi
(XP_002678320.1), but its primary sequence is closer to that of CYP51. In animals, lack of
22-desaturase is a typical feature. The 24-alkylation performed by ERG6 is present in Naegleria
but absent in animals.
The sterol metabolic network in N. fowleri
We used sterol biosynthesis inhibitors with different MOA to (i) interrogate the flux of sterol
intermediates, (ii) access the physiological requirement for specific sterols and (iii) identify
enzymatic chokepoints essential to trophozoite growth. The sterol biosynthetic cascade, recon-
stituted in N. fowleri based on the flux of the metabolic intermediates, is consistent with the
earlier data [20, 22] that sterol biosynthesis in Naegleria proceeds from cycloartenol (22) via
31-norlanosterol (14) to ergosterol (7) (Fig 1). Cholesterol (1), 7-dehydrocholesterol (7DHC)
(3), ergosterol (7) and its biosynthetic precursor ergosta-5,7-dienol (10) are the most abundant
sterols dominating lipid extracts of the non-inhibited N. fowleri and N. gruberi trophozoites,
whereas 4-monomethylsterols, 4,4-dimethyl intermediates and 14α-methylsterols are sparsely
represented (Table 1).
Given structural similarity of sterol substrates, enzyme specificity is controlled kinetically
rather than thermodynamically. Disruption of specific steps gives rise to the uncommon inter-
mediates that are enzymatically converted to the end-products not operational in the wild-
type organism. As reported previously,[22] upon treatment of N. fowleri with posaconazole,
the cumulative content of the 14α-methylsterols, including 12, 14, 16, 19, 20, 21 and 22,
increased from 6.5% to 49.1%, with the major intermediate being 31-norlanosterol (14) fol-
lowed by its C24-C25 hydrogenated product, 4,14-dimethylcholest-8-enol (12). Posaconazole
data reported elsewhere[22] are included in Table 1 as a comparative companion in the con-
text of the whole pathway. Given the unchanged content of 4,4-dimethylsterols in the CYP51
inhibitor-exposed samples, removal of the 4β-methyl group is unaffected by the blocking of
CYP51 activity and likely occurs prior to the C-14 demethylation; removal of the 4α-methyl
group occurs downstream to CYP51. The C-4 demethylation in two nonconsecutive steps is a
feature of land plants.[12] In this work, by using molecular probes with the corresponding
MOA, we mapped enzymatic steps downstream of CYP51, including sterol C8!C7-double
bond isomerization, catalyzed by ERG2, and sterol C24-methylation, catalyzed by SMT
(ERG6).
In an ERG2 inhibitor AY9944-treated N. fowleri, the 4α-methylcholesta-8,24-dienol (15)
content increased from zero to 19.1% suggesting that the 4α-demethylation follows the Δ8−Δ7
-isomerization and preferably occurs on 4α-methylcholesta-7,24-dienol (17). The treatment of
N. fowleri with another ERG2 inhibitor, tamoxifen, a non-steroidal estrogen receptor modula-
tor, also resulted in an increase of the ergosta-5,7-dienol (10) content from 21.3% to 43.5%
(Fig 1, Table 1), suggesting an inhibition of 22-desaturation performed by a yet unknown Nae-
gleria enzyme.
Exposure of N. fowleri to the SMT inhibitors 24,25-epiminolanosterol (epiminolanosterol),
abafungin and 25-azacycloartenol (25-Aza), led to high accumulation of cholesta-5,7,24-tri-
enol (6) (30% of total sterols), an intermediate undetectable in the wild-type or
Sterol homeostasis in N. fowleri
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posaconazole-inhibited N. fowleri (Table 1, Fig 2). This finding made three intermediates, 5, 8
and 6, potential candidates for endogenous SMT substrates in N. fowleri. All three contain a
Δ24(25) olefin group that allows C-methylation with formation of the transient 24-methylene
intermediate that ultimately is converted to the ergosterol-like physiological end-products (Fig
1).[24, 25] In the SMT-inhibited N. fowleri, the end-products 9 and 2, not operational in the
wild-type N. fowleri, were also formed. Accumulation of cholesta-5,7,22,24-tetraenol (9) and
cholesta-5,7,24-trienol (2), the end products representing a dysfunctional carbon flux, was pre-
viously reported in yeast carrying an ERG6 mutant defective in SMT activity.[26]
Functional analysis of Naegleria sterol C24-methyltransferase (SMT)
To identify what configuration of the double-bond(s) in the sterol B-ring favors Naegleria
SMT catalysis, the studies using recombinant enzyme and individually isolated sterol
Fig 1. Sterol metabolic network in N. fowleri. The pathway is reconstituted based on the metabolites observed in the untreated N. fowleri (shown in bold) and treated
with the CYP51 (shown in green), SMT (in blue) and ERG2 (in dark red) inhibitors. Metabolites not observed in the wild-type N. fowleri are depicted in thin lines. The
cholesterol arm of the pathway is highlighted by the yellow-green background, the ergosterol arm is highlighted by the blue background. Enclosed in frame are potential
SMT substrates. Enzymes interrogated in these studies are labeled in colors corresponding to the accumulating metabolites. Numbering of atoms in sterol molecule is
adapted from Nes and Venkatramesh, 1994.[41] Sterol labelling is as in Table 1. ERG enzyme nomenclature is according to the convention for S. cerevisiae.
https://doi.org/10.1371/journal.ppat.1007245.g001
Sterol homeostasis in N. fowleri
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intermediates were conducted. In the N. gruberi genome, two candidate genes encoding SMT
(77.6% sequence identity) were identified (S1 Table), which resemble those of higher plants in
primary sequence (~50% identity). Higher plants have two SMT enzymes that use different
substrates to give either C24-methylated or C24-ethylated phytosterols. N. fowleri has a single
gene encoding SMT; no 24-ethylated sterols were detected in the lipid extracts of any Naegleria
species. N. gruberi SMT (XP_002680047.1) sharing highest sequence identity (86%) with the
N. fowleri counterpart, has been expressed in Escherichia coli and recombinant protein was
characterized for substrate specificity. From the in vitro reconstitution of the SMT catalytic
activity, among thirteen sterols tested, 5 (zymosterol) and 6 (cholesta-5,7,24-trienol) were
equipotent as SMT substrates (set at 100%), while 8 (cholesta-7,24-dienol) showed 67.2% con-
vertion (Table 2).
An origin of cholesterol in Naegleria
Remarkably, in addition to the ergosterol ‘arm’ (highlighted blue in Fig 1), a cholesterol arm,
characterized by reactions 8!4!3!1 (highlighted orange in Fig 1), emerged in the
Table 1. Sterol flux in N. fowleri.
Non-inhibited CYP51 SMT Sterol Δ8−Δ7−isomerase
## Metabolitesa RRTb NG NFc Posaconazolec Epiminolanosterol Abafungin 25-Aza Tamoxifen AY9944
1 Cholesterol 1 7.6 25.6 26.0 15.6 2.0 12.7 3.0 9.5
4-Desmethylsterols (w/o cholesterol) 77.6 62.9 23.8 61.9 88.8 74.5 71.9 54.6
2 Cholesta-5,7,22-trienol 1 3.3 4.3 2.9
3 7-Dehydrocholesterol (7DHC) 1.04 10.8 12.5 3.9 9.9 13.8 12.9 4.1 7.5
4 Lathosterol 1.06 0.8 0.2
5 Zymosterol 1.07 0.4 0.1 0.1
6 Cholesta-5,7,24-trienol 1.11 30.8 30.0 38.8
7 Ergosterol 1.11 35.5 26.7 14.2 7.7 20.7 8.8 24.3 22.8
8 Cholesta-7,24-dienol 1.12 1.6 5.5 2.8
9 Cholesta-5,7,22,24-Tetraenol 1.20 6.9 8.6 5.3
10 Ergosta-5,7-dienol 1.21 31.1 21.3 5.7 1.6 5.7 2.9 43.5 24.3
11 Ergost-7-enol 1.22 0.2 1.2
4-Monomethylsterols 2.1 6.8 48.5 20.8 8.0 10.5 13.9 29.7
12 4α,14α-Dimethylcholest-8-enol 1.08 0.1 1.1 15.5
13 4α-Methylcholest-8-enol 1.11 3.5 0.4 7.6 7.2 2.6 10.4 5.7
14 31-Norlanosterol 1.14 2.0 2.2 29.7 0.5 1.4
15 4α-Methylcholesta-8,24-dienol 1.18 9.1 0.4 1.5 3.5 19.1
16 Δ7-31-norlanosterol 1.24 2.9
17 4α-Methylcholesta-7,24-dienol 1.26 3.6 0.4 5.0 2.9
18 4α-Methylergosta-8,24(28)dienol 1.31 2.0
4,4-Dimethylsterols 9.6 3.3 1.0 0.9 0.6 0.9 2.3 0.8
19 Lanostanol 1.30 0.5 0.2 0.2 0.4 0.5
20 Cycloartanol 1.32 6.9 1.1
21 Parkeol 1.40 0.3 0.1 0.1 0.3
22 Cycloartenol 1.41 1.9 2.0 0.7 0.4 0.1 0.6 2.3 0.8
Other sterols 3.1 1.4 0.7 0.8 0.6 1.4 8.9 5.4
aAll listed sterol structures are shown in Fig 1. The metabolites were quantified based on the total ion current peak areas of each sterol. NF–N. fowleri, NG–N. gruberi
bRelative retention time compared to cholesterol
cPreviously published data[22] used here as a comparative companion in the context of the whole pathway.
https://doi.org/10.1371/journal.ppat.1007245.t001
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metabolic flux studies. Together with the high cholesterol content, this observation raised a
question about the origin of cholesterol: de novo biosynthesis or scavenging from the growth
medium. To answer this question, we have conducted the 13C-labeling studies in N. gruberi
Fig 2. Lipid analysis by GC-MS. Gas chromatography of the total sterol fractions derived from N. fowleri trophozoites treated with (A) 0.5% DMSO, (B) 0.2 μM
posaconazole, (C) 5.4 μM epiminolanosterol, and (D) 5.6 μM AY9944. Peaks are labeled with numbers corresponding to metabolites listed in Table 1. Insert in (C)
shows deconvolution of the major peak resulting from an overlap of three different sterols: 6, m/z = 349; 7, m/z = 363 and 13, m/z = 400. The color scheme is the same as
in Fig 1: CYP51 inhibitor (shown in green), SMT inhibitor (in blue) and ERG2 inhibitor (in dark red).
https://doi.org/10.1371/journal.ppat.1007245.g002
Table 2. Conversion of different sterols by N. gruberiSMT.
Substrates Relative Activities (%)
fecosterol 0.0
24-methylenelophenol 0.0
zymosterol (5) 100.0
cholesta-5,7,24-trienol (6) 100.0
cholesta-7,24-dienol (8) 67.2
14α-methylzymosterol 29.0
desmosterol 17.10
4α-methylzymosterol 9.4
31-norlanosterol (14) 2.7
cycloartenol (22) 0.0
24-methylenecycloartenol 0.0
lanosterol (19) 0.0
obtusifoliol 0.0
https://doi.org/10.1371/journal.ppat.1007245.t002
Sterol homeostasis in N. fowleri
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grown in the ATCC1034 medium supplemented with U-13C glucose to the final concentration
of 5% (w/v). Incorporation of the 13C-carbon was monitored by GC/MS; a percent of the 13C
enrichment for each sterol was calculated from the isotopic distribution of the molecular mass
using IsoCor software.[27] As expected, cycloartenol, ergosta-5,7-dienol and ergosterol made
by amoeba biosynthetically, had the highest 13C-isotope content (Table 3). At the same time,
cholesterol was unlabeled, proving its exogenous origin in cultured N. gruberi trophozoites.
Remarkably, 13C-isotope content in 7-dehydrocholesterol (3) fall between the ergosterol and
cholesterol values, suggesting dual origin of this intermediate in both the de novo biosynthesis
and via a reverse reaction catalyzed in other species by cholesterol C-7 desaturase. Cholesterol
7-desaturase is a critical enzyme in insects and nematodes involved in the synthesis of steroid
hormones (DAF-36).[28] These lineages lack sterol biosynthesis capacity and rely solely on
cholesterol uptake from the diet. Both N. fowleri and N. gruberi genomes encode a putative
DAF-36-like protein (S1 Table).
The dual origin of 7DHC extends the cholesterol arm all the way from 8!4!3 (Fig 1).
The last 3!1 step separating N. fowleri from making cholesterol de novo, the reduction of the
C7-C8-double bond in 7-dehydrocholesterol usually performed by Δ7-dehydrocholesterol
reductase, remains unobserved. Candidates for this enzymatic role are present in both N. fow-
leri and N. gruberi genomes (S1 Table). A possibility of the pathway bifurcation downstream
of 8 suggests a “switch” between the C24-methylation and Δ24-reduction steps (Fig 1) commit-
ting Naegleria to either ergosterol or cholesterol biosynthesis, respectively. We hypothesize
that the switch may be used to maintain dynamic sterol homeostasis over the course of the N.
fowleri life-cycle.
Anti-proliferative and synergistic effects of sterol biosynthesis inhibitors
The growth inhibition of free-living amoebae by the sterol biosynthesis inhibitors has been
reported previously. Thus, the effect of the agricultural systemic fungicides, tridemorph and
fenpropimorph, which target both sterol Δ8−Δ7 -isomerase and Δ14-reductase,[29] has been
reported in Acanthamoeba polyphaga, N. lovaniensis and N. gruberi in the mid 80’s.[20, 21]
More recently, growth inhibition of Acanthamoeba castellanii and A. polyphaga was demon-
strated by the pharmaceutical sterol biosynthesis inhibitors, itraconazole and voriconazole, tar-
geting CYP51.[30] Finally, posaconazole and itraconazole were found superior to AmpB, a
cornerstone of PAM therapy and a standard of care for CNS infections caused by molds,
against N. fowleri trophozoites in vitro.[22] In this work, we demonstrated that blocking enzy-
matic steps downstream of CYP51, leads to a decline of ergosterol and/or accumulation of the
end-products and metabolic intermediates incompatible with N. fowleri survival in vitro. The
anti-proliferative effects of compounds were assessed using methods previously described.[7,
22] The EC50 values of the individual inhibitors deduced from the dose-response curves (Fig
3) are summarized in Table 4. For drug compatibility in combination experiments, all com-
pound stocks were prepared in DMSO, which negatively affected the isavuconazole and
Table 3. Isotopic enrichment of N. gruberi sterols incubated with 50 mM U-13C-glucose.
Sterols Molecular Formula 13C-content in normal medium (%) 13C-content in U13C-glucose medium (%)
Cholesterol C27H46O 1.07 1.06
Cholesta-5,7-dienol C27H44O 1.11 2.46
Ergosterol C28H44O 1.06 4.02
Erogsta-5,7-dienol C28H46O 1.11 4.03
Cycloartenol C30H50O 1.15 4.15
https://doi.org/10.1371/journal.ppat.1007245.t003
Sterol homeostasis in N. fowleri
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posaconazole EC50 values compared to previously determined for the SBE-β-CD-solubilized
drug.[22] The in vitro potency of all tested sterol biosynthesis inhibitors exceeded that of milte-
fosine (EC50 of 54.5 μM), an investigational drug currently recommended by the U.S. Centers
for Disease Control and Prevention for the treatment of PAM.
Blocking two essential enzymes in the ergosterol pathway is more detrimental for unicellu-
lar organisms than inhibiting one.[31] This synergistic effect is due to more efficient depletion
of an essential end product(s) and/or redirection of substrate flow to produce intermediates
and end-products harmful for key steroidogenic enzymes or membrane structures. In this
Fig 3. Dose-response growth inhibition of N. fowleri trophosoites. Dose-response curves are shown for (A) SMT
inhibitors: abafungin, 25-azacycloartenol and 24,25-epiminolanosterol, (B) ERG2 inhibitors: tamoxifen and AY9944,
(C) CYP51 inhibitor isavuconazole.
https://doi.org/10.1371/journal.ppat.1007245.g003
Sterol homeostasis in N. fowleri
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work, we have demonstrated synergy between the CYP51 (isavuconazole), SMT (epiminola-
nosterol) and sterol ERG2 (tamoxifen) inhibitors paired in three different combinations as
specified in Fig 4. Using classical isobolograms, combination indices (CI) and dose reduction
indices (DRI) were calculated from the experimental data (Fig 4A, 4B and 4C) as described by
Chou and Talalay (S2 Table). [32, 33] The isobolograms indicate synergy for all three drug
pairs in achieving 95% of N. fowleri growth inhibition with 2- to 19-fold dose reduction for isa-
vucanazole and 1- to 19-fold dose reduction for tamoxifen (Fig 4D); 3- to 109-fold dose reduc-
tion for epiminolanosterol and 2- to 16-fold dose reduction for tamoxifen (Fig 4E); and
finally, the highest synergy with 4- to 265-fold dose reduction for isavucanazole and 13- to
132-fold dose reduction for epiminolanosterol is indicated for the isavuconazole-epiminola-
nosterol pair (Fig 4F).
The drug combinations with the highest predicted synergy were analyzed microscopically
for their effect on N. fowleri growth and morphology (Fig 5). The isavuconazole-epiminola-
nosterol pair, combined at concentrations of 0.08 μM and 0.7 μM, respectively, (CI = 0.07)
(Fig 5A), the isavuconazole-tamoxifen pair, combined at 1.9 μM equimolar concentrations
(CI = 0.36) (Fig 5B), and epiminolanosterol and tamoxifen pair, combined at 2 μM equimolar
concentrations (CI = 0.38) (Fig 5C), completely inhibited the growth and led to the changed
morphology and death of the majority of N. fowleri cells in 48 h of drug exposure, whereas
DMSO-treated control cells grew and appeared normal (Fig 5D).
New therapeutic targets and blood-brain permeability of drugs
Drug ‘repurposing’ is a relevant and cost effective strategy for utilizing approved drugs for the
treatment of rare diseases. The requirement of brain penetrance narrows down the pool of the
Table 4. Targeting N. fowleri with inhibitors of known MOA.
Inhibitors EC50,
μM
N. fowleri
CYP51 (ERG11)
Posaconazolea 0.01[22]
Posaconazole 0.2±0.08
Isavuconazolea 0.1[22]
Isavuconazole 1.6±0.03
SMT (ERG6)
Abafungin 3.1±0.02
Epiminolanosterol 5.4±0.03
25-Azacycloartenol 14.3±0.04
Sterol Δ8−Δ7 isomerase (ERG2)
Tamoxifen 5.8±0.04
AY9944 5.6±0.03
Human σ1 receptor
Fluoxetine (Prozac) 31.8±0.01
Fluvoxamine (Luvox) 42% at 50 μM
Citalopram (Celexa) 21% at 50 μM
Dextromethorphan (DXM) 20% at 50μM
Standards of care
AmpBa 0.10±0.01[22]
Miltefosine 54.4±0.01[22]
asolubilised in SBE-β-CD
https://doi.org/10.1371/journal.ppat.1007245.t004
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Fig 4. Growth inhibition of N. fowleri as a function of drug combinations. Heat maps show growth inhibition of N. fowleri by drug combinations: tamoxifen and
isavuconazole (A), epiminlanosterol and tamoxifen (B), and epiminolanosterol and isavuconazole (C). Corresponding isobolograms (D, E, F) show the mean values of
dose reduction index (DRI) ploted against calculated inhibitor doses required to achieve 95% growth inhibition. Standard deviations for each parameter mean value are
shown in S2 Table.
https://doi.org/10.1371/journal.ppat.1007245.g004
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FDA-approved candidates for the treatment of PAM. Only a few diseases of the brain like
depression, affective disorders, chronic pain, and epilepsy respond to small-molecule therapy.
The reason for the paucity of small-molecule drugs is that 98% of them do not cross the blood-
brain barrier (BBB).[34, 35] Validation of sterol Δ8−Δ7 -isomerase (ERG2) as a new potential
molecular drug target in N. fowleri provides a link to structurally diverse brain-penetrant
small-molecule drugs targeting human non-opioid σ1 receptor sharing 30% sequence identity
and 60% sequence homology to the catalytic domain of the N. fowleri sterol Δ8−Δ7 -isomerase
(Fig 6). The non-opioid σ1 receptor is implicated in human CNS conditions such as addiction,
amnesia, pain and depression.[36]
We have tested four non-selective serotonin reuptake inhibitors (SSRIs) and σ1 receptor
agonists with reported affinity to human σ1 receptors, fluvoxamine (Luvox), fluoxetine (Pro-
zac), citalopram (Celexa) and dextromethorphan (DXM), [37, 38] for growth inhibition
against N. fowleri. All four drugs demonstrated effect at the highest tested concentration
Fig 5. Synergistic effect of drugs at low concentrations. The phase contrast microscope images show N. fowleri
trophozoites treated for 48 hours with (A) 0.08 μM of isavuconazole and 0.7 μM of epiminolanosterol, (B) 1.9 μM
equimolar concentrations of isavuconazole and tamoxifen, (C) 2 μM equimolar concentrations of epiminolanosterol
and tamoxifen, and (D) 0.5% DMSO, which served as a negative control. The inhibitor-treated N. fowleri cells visible in
the microscope field are rounded, much smaller in size and not viable, whereas DMSO-treated cells are irregularly
shaped with visible cytoplasm. Magnification, ×20.
https://doi.org/10.1371/journal.ppat.1007245.g005
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(50 μM). Fluoxetine, the well-known antidepressant, was the most potent in this group
(Table 4). Potency of fluoxetine (EC50 of 32 μM) exceeded that of miltefosine (54 μM). Other
structurally diverse brain-penetrant small-molecule drugs targeting this human receptor will
now be screened for anti-Naegleria activity to identify candidates for animal model studies.
Summary
The sterol biosynthetic pathway in N. fowleri displays a mixture of canonic features peculiar to
different domains of life: lower eukaryotes, land plants, invertebrates and vertebrates. In addi-
tion to the cycloartenol!ergosterol biosynthetic route, our data suggest a route leading to de
novo cholesterol biosynthesis with a single, yet to be experimentally observed, enzymatic step
separating N. fowleri from making cholesterol de novo. N. fowleri also utilizes cholesterol
obtained from diet by converting it into 7-dehydrocholesterol, a feature typical to the eukary-
ote lineages (e.g., insects, worms and marine invertebrates) that lost the ability to produce ste-
rols from squalene. Hypothetically, a “switch” between ergosterol and cholesterol sterol types
may occur in Naegleria, e.g., during encystation/excystation, to sustain environmental chal-
lenges by forming a viable cyst. By demonstrating the amoebicidal effect of the sterol biosyn-
thesis inhibitors with different MOA, we validated multiple, potentially druggable, molecular
targets in N. fowleri, linking the anti-Naegleria drug discovery to the existing small-molecule
drugs targeting other human diseases. Synergy between alternative drug-targets is of interest
for the treatment of PAM, as lower drug concentrations are required to achieve the biologic
effect. Reducing therapeutic concentrations may, in part, alleviate the limitation imposed by
the need of delivering anti-PAM drugs accross the blood-brain-barrier.
Materials and methods
Ethics statement
Research performed at UC San Diego was conducted in compliance with the Animal Welfare
Act and other federal statutes and regulations relating to animals and experiments involving
animals and adheres to the principles stated in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 2011. The facility where this research was conducted is
fully accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care International. Animal research was conducted under approved protocol S14187 from the
Institutional Animal Care and Use Committee, University of California, San Diego.
Fig 6. Sequence alignments between the catalytic domain of sterol Δ8−Δ7 -isomerase (ERG2) and a ligand binding site of non-
opioid σ1 receptor (SGMR1) demonstrate high sequence similarity. Accession numbers in UniProt or AmoebaDB are provided for
each sequence. Numbering is according to the Dictyostelium discoideum ERG2 sequence.
https://doi.org/10.1371/journal.ppat.1007245.g006
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Euthanasia was accomplished by CO2 inhalation or by sodium pentobarbital overdose (60 mg/
kg), followed by cervical dislocation. These methods of euthanasia have been selected because
they cause minimal pain and distress to animals, are relatively quick, and do not adversely
impact interpretation of the results of studies. All methods are in accord with the recommen-
dations of the Panel on Euthanasia of the American Veterinary Medical Association.
Compounds
The inhibitors tested were purchased from commercial vendors except epiminolasosterol and
25-azacycloartenol which were synthesized in Dr. Nes’ laboratory; the structure of the sterol
was authenticated by both the GC-MS and NMR methods. AY9944 and abafungin were from
Santa Cruz Biotechnology (SC-202965 and SC-474844); tamoxifen was from Sigma (T5648),
isavuconazole was from StruChem (SC-98350), fluvoxamine (J90043), fluoxetine (C845), cita-
lopram (K750) and dextromethorphan (X3585) were from AK Scientific.
N. fowleri strain maintenance
The N. fowleri KUL strain used in these studies was acquired from ATCC in 2015; aliquoted
stock is maintained deep frozen in liquid nitrogen. N. fowleri amoebae maintained axenically
(in culture) are weakly virulent. To maintain highly virulent status, N. fowleri strain is passaged
every six months in mouse brain. For that, four week-old male Balb/c mice are inoculated by
intranasal instillation of 10 μl of 3x104 N. fowleri trophozoites axenically cultured at 37˚C in
Nelson’s medium supplemented with 10% fetal bovine serum, resulting in 100% animal mor-
tality at day 7. Female mice are less susceptible to N. fowleri infection, therefore only male mice
are used in this model. At the time point when clinical signs of infection are apparent, the
mice are sacrificed and the brains are harvested to propagate N. fowleri axenically for the next
few months. The animals and tissues infected with N. fowleri are handled in the certified Bio-
safety Level-2 (BSL-2) environment according to the UCSD Institutional Animal Care and
Use Committee guidelines and approved animal protocol. Safety glasses, gloves, mask, disposal
gowns, shoe covers and head cover are worn. N. fowleri strain is handled in a biosafety cabinet
mounted in the BSL-2 environment.
N. fowleri growth inhibition assay
To determine EC50 values, test compounds were tested for dose-response against N. fowleri
trophozoites axenically cultured in Nelson’s medium supplemented with 10% fetal bovine
serum at 37˚C;[39] all the experiments were performed in triplicate using trophozoites har-
vested during the logarithmic phase of growth.[40] Drug concentration ranges of 0.4–50 μM
and 0.008–25 μM were generated by transferring 0.5 μl of serially diluted compounds to a cor-
responding well of the 96-well plate followed by addition of 99.5 μl of N. fowleri trophozoites
(10,000 amoebae). Assay plates were incubated for 48 h and cell viability was determined by
the CellTiter-Glo Luminescent Cell Viability Assay.[7, 40] The experiments using trophozoites
were conducted in a biosafety cabinet following the BSL-2 procedures as specified in the
UCSD Biosafety Practices Guidelines.
GC-MS analysis of the Naegleria sterols
Twenty or fifty million N. gruberi or N. fowleri trophozoites per sample were exposed for 24 h
to 0.5% DMSO or an inhibitor at EC50 concentration prior to lipid extraction. Sterols were
analyzed by the use of GC-MS, wherein the lipids extracted from cells grown in the presence
of non-lethal concentrations of inhibitors are separated by gas chromatography and
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subsequently analyzed by mass-spectrometry, as previously described.[22] The sterol identities
were assigned based on relative chromatographic behavior, the characteristic molecular masses
and electron ionization (EI) fragmentation patterns of free sterols (Fig 2). The sterols were
quantified based on the total ion current peak areas of each sterol.
Catalytic activity of recombinant SMT
The cDNA coding sequence for XP_002680047 was retrieved from NCBI database and the
gene was synthesized by Eurofin MWG (Huntsville, AL). The gene was cloned into the PQE30
plasmid (Qiagen) and expressed in E. coli M15 strain. Briefly, the M15 E.coli cells harboring
expression vector were grown at 37˚C in Luria broth (LB) containing ampicillin and kanamy-
cin until OD600 reached 0.6. The gene expression was induced by 1.0 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG) for 6 hours. The cells were collected by centrifugation and
homogenized in 20 mM phosphate buffer in 5% (v/v) glycerol at pH 7.5. After removal of the
cell debris by centrifugation at 100,000×g, the soluble fraction was analyzed by Bradford assay
to determine the total protein concentration.
To assess the catalytic activity of SMT, thirteen different sterol substrates specified in
Table 2 were used. Enzymatic assays were carried out using crude SMT preparation in 9-ml
test tubes containing a total of 600 μl assay volume at 35˚C for 4 hours. The assay mixture con-
tained 100 μM sterol emulsified in 12 μl Tween 80 (1.2g/L) and 1.2 mg of total protein. The
reaction was initiated by the addition of 200 μM of S-adenosyl methionine. The reactions were
terminated with 1 ml of methanolic KOH. Sterols were extracted with hexane (3 x 1 ml) and
dried under an N2 stream. The extracted sterols were separated by GC/MS and the substrate
conversion rate (R) was calculated from the GC peak areas for the substrate (S) and the prod-
uct (P) peaks according to the following equation: R = 1-P/(S+P). The conversion rates were
normalized to the activity of the two best substrates, 5 and 6, which was considered as 100%.
Validation of the inhibitors for growth inhibition activity
Compounds were tested against N. fowleri KUL trophozoites axenically cultured in Nelson’s
medium supplemented with 10% fetal bovine serum at 37˚C.[22] All the experiments were
performed using trophozoites harvested during the logarithmic phase of growth. Screening
was performed in triplicate by using an ATP bioluminescence-based assay[40] as previously
described.[22] The experiments using trophozoites were conducted in a biosafety cabinet fol-
lowing the BSL2 procedures as specified in the UCSD Biosafety Practices Guidelines.
Determination of FIC indices and isobologram construction
To determine if the combinations between the inhibitors are synergistic, additive, or antago-
nistic against N. fowleri trophozoites, classical isobolograms were used, and combination indi-
ces (CI) were calculated as described by Chou and Talalay.[32, 33] Briefly, compounds
(epiminolanosterol/tamoxifen, isavuconazole/epiminolanosterol, isavuconazole/tamoxifen)
were combined at different micromolar ratios (1:1, 1:2, 1:4, 1:8, 1:16, 2:1, 4:1, 8:1 and 16:1) at
each drug concentrations ranging from 50 μM to 0.4 μM (Fig 4). Effect for drug pairs was
assessed in triplicate in 96-well format with each drug being serially diluted either horizontally
or vertically. Growth inhibition was assessed after 48 h using an ATP bioluminescence-based
assay.[22]. The results were analyzed using CompuSyn software[32] that calculated combina-
tion indices serving as a quantitative measure for drug synergy (CI<1), additivity (CI = 1), or
antagonism (CI>1). The dose reduction index (DRI), a fold of dose reduction that allows drug
combination to achieve the same degree of inhibition as a dose of the drug used as a single
agent, was also calculated by the CompuSyn software.
Sterol homeostasis in N. fowleri
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007245 September 13, 2018 15 / 18
The predicted synergistic effect of drugs was experimentally tested in a 96-well clear bottom
plate. N. fowleri trophozoites (1×104) were treated with pairs of compounds (isavuconazole/
epiminolanosterol, isavuconazole/tamoxifen and epiminolanosterol/tamoxifen) mixed at con-
centrations that provided the highest CI at 48 h. Cells treated with 0.5% DMSO were used as
control. After 48 hours, wells were visually inspected using an Axiovert 40 CFL phase contrast
microscope (Carl Zeiss).
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